Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings
BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of
novel therapies for life-threatening diseases and other public health threats, today announced that leading independent proxy advisor Institutional Shareholder Services Inc. (“ISS”) has recommended
that stockholders vote FOR the Company's previously announced definitive agreement to be acquired by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo
Holdings").
ISS is an independent proxy advisory firm whose clients include many of the world's leading institutional investors. Such investors rely on ISS’s objective and impartial analysis to make important voting decisions.
“We are pleased to receive ISS’s independent recommendation for the transaction. The transaction was the result of a robust process led by the independent members of the Board and offers stockholders immediate value, liquidity, certainty of the upfront cash payment and upside participation through the CVR. Stockholders are encouraged to vote FOR the transaction today,” said Dr. Jeffrey Stein, Ph.D., Lead Independent Director of Paratek’s board of directors (the “Board”).
Stockholders are urged to vote online today to ensure their votes are received on time. The deadline for online votes to be received is 11:59pm on September 17, 2023.
Stockholders who have questions about voting their proxy are encouraged to contact our proxy solicitor Morrow Sodali LLC at +1 (800) 662-5200 (toll-free in North America), +1 (203) 658-9400 (collect outside of North America) or PRTK@info.morrowsodali.com
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats.
Lesen Sie auch
The company's lead commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.